Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

Engineered herpes virus activates potent immune responses against glioblastoma

Engineered herpes virus activates potent immune responses against glioblastoma

Focused ultrasound combined with chemotherapy improves survival in glioblastoma patients

Focused ultrasound combined with chemotherapy improves survival in glioblastoma patients

Intranasal nanomedicine shows promise against glioblastoma

Intranasal nanomedicine shows promise against glioblastoma

RNA-based cocktail shows promise against glioblastoma

RNA-based cocktail shows promise against glioblastoma

Engineered CAR-T cells show promise against glioblastoma in preclinical models

Engineered CAR-T cells show promise against glioblastoma in preclinical models

New NIH grants support research on how brain fluid movement drives glioblastoma spread

New NIH grants support research on how brain fluid movement drives glioblastoma spread

New insights into glioblastoma survival linked to brain fluid dynamics

New insights into glioblastoma survival linked to brain fluid dynamics

LRIG1 could serve as important biomarker to distinguish between glioma types and grades

LRIG1 could serve as important biomarker to distinguish between glioma types and grades

Northwestern team develops antibody to expose hidden pancreatic cancer cells

Northwestern team develops antibody to expose hidden pancreatic cancer cells

Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies

Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies

Multimodal nanocarriers offer targeted solutions for tumor treatment

Multimodal nanocarriers offer targeted solutions for tumor treatment

Multidimensional regulation of stem cell fate by the cohesin complex

Multidimensional regulation of stem cell fate by the cohesin complex

Discovery of unique brain cells sheds light on progressive multiple sclerosis

Discovery of unique brain cells sheds light on progressive multiple sclerosis

Engineered virus therapy triggers powerful immune responses in glioblastoma

Engineered virus therapy triggers powerful immune responses in glioblastoma

Repeated sampling offers insight into glioblastoma therapy response

Repeated sampling offers insight into glioblastoma therapy response

Deadly brain cancer erodes skull bone and alters immune marrow

Deadly brain cancer erodes skull bone and alters immune marrow

Proton therapy dose escalation may improve outcomes for glioblastoma patients

Proton therapy dose escalation may improve outcomes for glioblastoma patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.